Clinical Trial Update: FAPi PET in Pancreatic Ductal Adenocarcinoma

View source ↗

Summary

A clinical trial is evaluating a fibroblast activation protein inhibitor (FAPi) PET imaging agent for pancreatic ductal adenocarcinoma and is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FAPi-PET imaging agent (Fibroblast Activation Protein imaging tracer)

Snippet

Sponsor: Tata Memorial Hospital | Conditions: Pancreatic Cancer, Adenocarcinoma Pancreas | Status: RECRUITING